Mobile

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneou...

Update Il y a 4 ans
Reference: EUCTR2009-015845-21

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the change in DAS28 from baseline to Week 24 for patients on tocilizumab (TCZ) vs adalimumab (ADA).

Inclusion criteria

  • Adult Rheumatoid Arthritis (RA)

Links